Abstract: The present invention is directed to olfactory diagnostic testing compositions and kits for detecting, screening and/or monitoring the progression of specific disease states or other conditions in a subject. In one aspect, the invention is directed to a method and testing kit using a pathology-specific panel of fragrances to detect, screen and/or monitor a specific disease state or condition. In another aspect, the invention is directed to a method of making diagnostic compositions having a specific complex fragrance such as an essential oil fragrance and diagnostic testing kits including such diagnostic compositions.

Abstract: A modular in vitro device can be configured as a subcutaneous absorption model. The in vitro device can include a center chamber and a matrix material configured to be included in the center chamber during measurement of absorption of a test agent. A first side chamber is configured to couple with the center chamber, with least one first side opening configured to fluidly couple with the center chamber. A first membrane is configured to be positioned between the center chamber and first side. A second side chamber similar to the first side chamber is provided, with a second membrane configured to be positioned between the center chamber and second side chamber. The center chamber, first side chamber, and second side chamber are configured to be modular for combining with the first membrane and second membrane in a lateral arrangement.

Abstract: This hinge cover assembly provides a cover member, stopping member, and fastener mechanism that work in tandem to stop the relative rotation of objects along an axis. This improved hinge cover assembly can be incorporated into multiple hinged object assemblies, including doors, windows, and cabinets.

Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.

Abstract: A power amplifier is configured to operate in a first gain mode and a second gain mode. A first power amplifier input stage has an input and an output. A second power amplifier input stage has an input and an output, where the output of the second power amplifier input stage is coupled to the output of the first power amplifier input stage. The first input stage is turned on in response to a first bias voltage in the first gain mode and the second input stage is turned on in response to a second bias voltage in the second gain mode. Alternatively, a first input stage and an intermediate stage can be switched off by turning off their respective bias voltages, and a second input stage can be switched on by turning on its respective bias voltage; the intermediate stage and the second input stage sharing a common output.

Abstract: A method and apparatus for biasing an amplifying device whereby the bias current tracks the input power or the power level of a control signal to thereby efficiently match the bias current with needs of the amplifying device. This method and apparatus overcomes the drawbacks of the prior art by biasing, not for maximum output power, but for the power level of the input signal or the control signal. In one embodiment a current conditioner operates in connection with the self adjusting biasing circuit to scale or adjust, potentially on an exponential basis, the biasing current for one or more amplifier stages. A cancellation current source may be configured within the bias circuit to cancel unneeded current to further minimize current consumption.

Abstract: The selective cyclooxygenase-2 inhibitory drug celecoxib is provided in amorphous form. Also provided is a celecoxib drug substance wherein the celecoxib is present, in at least a detectable amount, as amorphous celecoxib. Also provided is a celecoxib-crystallization inhibitor composite comprising particles of amorphous celecoxib or a celecoxib drug substance of the invention in intimate association with one or more crystallization inhibitors, for example polymers. Also provided is a pharmaceutical composition comprising such a celecoxib-crystallization inhibitor composite and one or more excipients. Also provided are processes for preparing amorphous celecoxib, a celecoxib drug substance of the invention, a celecoxib-crystallization inhibitor composite of the invention, and a pharmaceutical composition of the invention.

Abstract: A method of tuning the frequency response of filters embedded in or formed on a ceramic substrate, such as but not limited to a low temperature co-fired ceramic substrate (LTCC), by re-firing a previously fired LTCC substrate to a temperature which is greater by a predetermined, relatively small, amount than that of the temperature produced during the original firing profile of the substrate so as to change the dielectric constant of the substrate, and thus cause a desired shift in the filter's frequency response.